

Antimicrobial resistance patterns of *Acinetobacter baumannii* and *Klebsiella pneumoniae* isolated from dogs presented at a veterinary academic hospital in South Africa

Dikeledi C. Sebola¹ , James W. Oguttu² , Marleen M. Kock^{3,4} , and Daniel N. Qekwana¹ 

1. Section Veterinary Public Health, Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa; 2. Department of Agriculture and Animal Health, College of Agriculture and Environmental Sciences, University of South Africa, Johannesburg, South Africa; 3. Department of Medical Microbiology, University of Pretoria, Pretoria, South Africa; 4. Tshwane Academic Division, National Health Laboratory Service, Pretoria, South Africa.

Corresponding author: Dikeledi C. Sebola, e-mail: dc.sebola@gmail.com

Co-authors: JWO: joguttu@unisa.ac.za, MMK: marleen.kock@up.ac.za, DNQ: nenene.qekwana@up.ac.za

Received: 13-05-2023, **Accepted:** 22-08-2023, **Published online:** 17-09-2023

doi: www.doi.org/10.14202/vetworld.2023.1880-1888 **How to cite this article:** Sebola DC, Oguttu JW, Kock MM, and Qekwana DN (2023) Antimicrobial resistance patterns of *Acinetobacter baumannii* and *Klebsiella pneumoniae* isolated from dogs presented at a veterinary academic hospital in South Africa, *Veterinary World*, 16(9): 1880–1888.

Abstract

Background: *Acinetobacter baumannii* and *Klebsiella pneumoniae* are opportunistic bacterial pathogens responsible for hospital-acquired infections in veterinary medicine. Infection with these bacteria always requires urgent antimicrobial therapy. However, there is no evidence of studies that have investigated the antimicrobial drug resistance profile of these organisms in a veterinary setting in South Africa. This study investigated the antimicrobial resistance (AMR) patterns of *A. baumannii* and *K. pneumoniae* from clinical specimens obtained from dogs presented at a veterinary academic hospital. The findings of this study contribute to an improved understanding of the AMR profile of these bacteria in veterinary medicine.

Materials and Methods: Retrospective data of clinical samples from dogs that were positive for *A. baumannii* and *K. pneumoniae* between 2007 and 2013 were used in this study. The antimicrobial susceptibility of the isolates was determined using the disk diffusion method following the Clinical and Laboratory Standards Institute guidelines. The *A. baumannii* isolates were subjected to a panel of 20 antibiotics, while *K. pneumoniae* isolates were subjected to a panel of 22 antibiotics. Data were analyzed using descriptive statistics and presented using tables and figures.

Results: Twenty (n = 20) *A. baumannii* isolates were isolated from bronchoalveolar lavage, foreign objects, bone, urine, skin, blood, ear, nasal, and oral cavity. Almost all *A. baumannii* (95%, 19/20) isolates were resistant to at least one antibiotic, and 60% (12/20) were multidrug-resistant (MDR). *Klebsiella pneumoniae* (n = 56) was isolated from urine, foreign objects, abscesses, ears, eyes, tracheal aspirations, bronchoalveolar lavages, eyes, abdominal aspirates, anal glands, bones, and intestinal and lung biopsies. All *K. pneumoniae* (100%, 56/56) isolates were resistant to at least one antibiotic, and 98% (55/56) were MDR.

Conclusion: Both *A. baumannii* and *K. pneumoniae* were isolated in various clinical tissue samples and exhibited a high prevalence of resistance to multiple antibiotics. In addition, these bacteria exhibited a high prevalence of resistance to β -lactam compared to other classes of antibiotics, which is likely to impact treatment options and patient prognosis.

Keywords: *Acinetobacter baumannii*, antimicrobial resistance, dogs, ESKAPE, *Klebsiella pneumoniae*, multidrug resistance, veterinary hospital.

Introduction

Acinetobacter baumannii and *Klebsiella pneumoniae* belong to the group of bacteria termed “ESKAPE” pathogens, and they are responsible for outbreaks in clinical settings across the globe [1]. This ESKAPE group of bacteria is known to escape the biocidal action of antimicrobials and is associated with increased mortality and healthcare costs in both human and animal medicine [1]. In addition, these bacterial species are among the pathogens for which

urgent antimicrobial therapy is required due to their tendency to exhibit a high prevalence of multidrug resistance (MDR) [1, 2].

Acinetobacter baumannii is an opportunistic pathogen that usually affects immunocompromised patients [3]. It is a non-motile, aerobic, oxidase-negative, and non-fermentative coccobacilli Gram-negative bacterium [4]. It is ubiquitous and has been isolated from drinking water, food, and soil [4, 5]. *Acinetobacter baumannii* can survive for long periods on dry surfaces. As a result, surfaces of inanimate objects in hospitals can be a source of infection for patients [4, 6]. In humans, *A. baumannii* has been isolated from clinical infections such as pneumonia, bloodstream infections, skin and soft-tissue infections, urinary tract infections (UTIs), and meningitis, while it has been isolated from UTIs, bloodstream infections, and

Copyright: Sebola, et al. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

wound infections in dogs [4, 5]. *Acinetobacter baumannii* associated with hospital-acquired infections is MDR and has a high prevalence of resistance to the β -lactam and cephalosporin groups of antibiotics [4]. The high prevalence of resistance to these groups of antibiotics can be attributed to various reasons, including the natural resistance due to the interplay between the outer membrane that provides protection, active efflux pump systems, and the low expression of small-aperture outer membrane porins. [6]. *Klebsiella pneumoniae* is a facultative, anaerobic Gram-negative bacterium belonging to the *Enterobacteriaceae* family. It is an intestinal commensal; however, it has been reported in gastrointestinal diseases, UTIs, pneumonia, bacteremia, pyogenic liver abscesses, and burn and wound infections in both humans and animals [6, 7]. Together with *Escherichia coli*, these bacteria are among the most prevalent organisms in hospital and community settings [6, 8]. *Klebsiella pneumoniae* is an opportunistic pathogen in young, old, and immunocompromised humans [6]. It is an important cause of hospital-acquired wound infections and UTIs in humans [7]. In animals, the bacterium has been reported to cause clinical mastitis, pneumonia, septicemia, bacteremia, UTIs, and polyarthritis [7]. *Klebsiella pneumoniae* exhibits a high prevalence of resistance to multiple antibiotics [6, 7, 9]. It acquires and disseminates resistant genes, including those encoding for the extended spectrum β -lactamases, resulting in resistance to β -lactam antibiotics, including penicillin, cephalosporins, and the monobactam aztreonam [6, 9], and, therefore, limiting treatment options [8, 9].

In South Africa, studies of ESKAPE pathogens have been well-documented in human medicine [2, 10, 11]. However, studies investigating antimicrobial drug resistance among the ESKAPE group of pathogens in veterinary medicine are limited. This study aimed to investigate the antimicrobial resistance (AMR) patterns of *K. pneumoniae* and *A. baumannii* isolated from clinical samples of dogs presented at a veterinary teaching hospital. The findings of this study will contribute to a better understanding of antibiotic resistance among *K. pneumoniae* and *A. baumannii* isolates of veterinary origin. In addition, it is envisaged that information generated from this study will be used to guide the treatment of *K. pneumoniae* and *A. baumannii* infections and improve treatment outcomes in a veterinary setting [6].

Materials and Methods

Ethical approval

Written consent granting the Academic Teaching Hospital permission to use information obtained from dogs presented at the hospital for teaching and research purposes was obtained from the owners of the dogs. In addition, this study followed all ethical standards for research without direct contact with

human or animal subjects. Ethical clearance was also obtained from the University of Pretoria's Faculty of Veterinary Science Research Ethics Committee, Faculty of Humanities Research Ethics Committee (Project number: REC009-21), and Faculty of Health Sciences Research Ethics Committee (Reference No: 187/2022).

Study period and location

The retrospective data were processed in November 2022 and analyzed from January 2023 to April 2023. This study was conducted at a veterinary academic hospital in Pretoria, South Africa. The hospital provides clinical services for companion, livestock, and wildlife animals. In addition, the hospital serves as a referral center for internal medicine and surgical cases for clients in and around Pretoria. The bacteriology laboratory in the Department of Veterinary Tropical Diseases that cultured the isolates provides a service to the veterinary academic hospital for routine clinical diagnosis of suspected infectious diseases.

Data source

Retrospective data records of dog clinical samples submitted to the Bacteriology Laboratory from January 2007 to December 2013 were used in the study. For each isolate, the following information was extracted from the paper records: the patient's unique number, specimen type, date of sample collection, organ system, and antimicrobial susceptibility test results of the isolates. The data were then entered and stored in an electronic database for analysis.

Bacterial isolates and antimicrobial susceptibility testing

All the submitted clinical samples were cultured to isolate *A. baumannii* and *K. pneumoniae* using standard bacteriological methods described by Ricketts [12]. Antimicrobial susceptibility testing was performed using the disk diffusion method following Clinical Laboratory Standards Institute (CLSI) guidelines (CLSI 2007, 2008, 2009, 2010, 2011, and 2012) to conduct antimicrobial susceptibility testing.

Acinetobacter baumannii isolates were subjected to a panel of 20 antibiotics: amikacin (30 μ g), ampicillin (10 μ g), carbenicillin (100 μ g), ceftazidime (30 μ g), cephalothin (30 μ g), chloramphenicol (30 μ g), enrofloxacin (5 μ g), gentamicin (10 μ g), imipenem (10 μ g), kanamycin (30 μ g), lincomycin (10 μ g), lincomycin-spectinomycin (100 μ g), orbifloxacin (5 μ g), oxytetracycline (30 μ g), penicillin G (10 μ g), piperacillin (100 μ g), trimethoprim-sulphamethoxazole (25 μ g), amoxicillin/clavulanic acid (20/10 μ g), tobramycin (10 μ g), and tylosin (15 μ g) (Oxoid Ltd., Cambridge, UK).

Klebsiella pneumoniae isolates were subjected to a panel of 22 antibiotics: amikacin (30 μ g), ampicillin (10 μ g), carbenicillin (100 μ g), ceftazidime (30 μ g), cephalothin (30 μ g), chloramphenicol (30 μ g), enrofloxacin (5 μ g), erythromycin (15 μ g), gentamicin

(10 µg), imipenem (10 µg), kanamycin (30 µg), lincomycin (10 µg), lincomycin-spectinomycin (100 µg), orbifloxacin (5 µg), oxytetracycline (30 µg), penicillin G (10 µg), piperacillin (100 µg), rifampin (30 µg), trimethoprim-sulphamethoxazole (25 µg), amoxicillin/clavulanic acid (20/10 µg), tobramycin (10 µg), and tylosin (15 µg) (Oxoid Ltd.).

The results of antibiograms were classified as intermediate, susceptible, or resistant, following the CLSI guidelines (CLSI, 2007, 2008, 2009, 2010, 2011, and 2012). For the purposes of this study, resistance to at least one antibiotic was classified as AMR. Multidrug resistance was defined as resistance to at least one antibiotic in three or more antibiotic categories [13].

Antimicrobials to which the bacteria have an inherent resistance were excluded from MDR analysis. For example, *K. pneumoniae* is known to be inherently resistant to ampicillin, carbenicillin, and erythromycin. Therefore, these groups of antibiotics were excluded from the MDR analysis. Since *A. baumannii* is inherently resistant to penicillins and lincosamides, these two groups were excluded from the analysis to determine the prevalence of MDR. In addition, antibiotics were excluded from the MDR analysis if all isolates were not tested to determine their susceptibility to these antibiotics. Therefore, imipenem, tobramycin, rifamycin, and ceftazidime were excluded from the analysis to determine MDR isolates for *K. pneumoniae*, and imipenem, tobramycin, and ceftazidime were excluded from the analysis to determine MDR isolates for *A. baumannii*.

Data management and analysis

The dataset was assessed for duplicates and missing information, such as the lack of antibiogram results. Some isolates had missing information, but there were no duplicates in the dataset. Isolates from specimens such as endotracheal tubes, screws, pins, wires, catheter tips, nails, and plates were classified as “foreign objects,” while specimens such as lung, liver, spleen, lymph node, heart, and kidney were reclassified as “organ pool.” Crude percentages of isolates of *A. baumannii* and *K. pneumoniae* that were AMR and MDR were computed and presented as figures and tables. All statistical analyses were performed using the statistical analysis system.

Results

Acinetobacter baumannii

A total of 20 *A. baumannii* were isolated over the study period with six (n = 6; 30%) from bronchoalveolar lavage and three (n = 3; 15%) from foreign objects. *Acinetobacter baumannii* was also isolated from various samples/tissues such as bone, urine, skin, blood, ear, nasal, and oral cavity (Figure-1).

Nineteen isolates were AMR (95%, 19/20) with the majority of *A. baumannii* isolates showing resistance to penicillin G (85%) and ampicillin (65%). Forty-five percentages (45%, 9/20) of




Figure-1: Distribution of *Acinetobacter baumannii* in the various canine samples tested by the bacteriology laboratory at the faculty of veterinary science between 2007 and 2013.

the isolates were resistant to amoxicillin/clavulanic acid. All five isolates (100%) tested were resistant to carbenicillin, piperacillin, and ceftazidime. A high prevalence of resistance was recorded against lincomycin (95%), tylosin (68%), chloramphenicol (60%), lincomycin-spectinomycin (60%), and cephalexin (60%). A low prevalence of resistance among the *A. baumannii* was reported for aminoglycosides, except for tobramycin. Similarly, low resistance was observed against fluoroquinolones, tetracycline, and potentiated sulfonamides. One out of four (1/4, 25%) isolates was resistant to imipenem (Table-1).

Sixty percentages (60%, 12/20) of *A. baumannii* isolates were MDR. A high proportion of isolates exhibited resistance to cephalothin (92%), followed by chloramphenicol, trimethoprim-sulphamethoxazole, enrofloxacin, amoxicillin/clavulanic acid, and kanamycin, to which 75% of the isolates were resistant (Table-1). Three (n = 3) MDR *A. baumannii* isolates were resistant to ten antimicrobials, two (n = 2) to nine antimicrobials, and one (n = 1) to eight antimicrobials (Table-2).

Klebsiella pneumoniae

A total of 56 *K. pneumoniae* isolates were recorded. Of these, 39% (22/56) were isolated from urine followed by 9% (5/56) from foreign objects. Very low proportions were isolated from abscesses, ears, eyes, transtracheal aspirations, bronchoalveolar lavage, abdominal aspirates, anal glands, bones, intestinal biopsies, and lung biopsies (Figure-2).

All *K. pneumoniae* isolates (56; 100%) were resistant to penicillin G, amoxicillin, carbenicillin, piperacillin, ceftazidime, and lincomycin. Sixty-four percentages (35/56) of the isolates were resistant to cephalexin and 60% to amoxicillin/clavulanic acid. None of the isolates tested were resistant to

Table-1: Antimicrobial resistance and multidrug resistance profile of *Acinetobacter baumannii* isolated from canine clinical samples tested at a veterinary academic hospital, in South Africa.

Antimicrobial category	Resistant	
	Isolates (n) %	MDR isolates (n) %
Macrolides		
Tylosine	68 (13/19)	-
β-lactams		
Penicillins		
Ampicillin	65 (13/20)	-
Carbenicillin	100 (5/5)	-
Penicillin G	85 (17/20)	-
Piperacillin	100 (5/5)	-
Cephalosporins		
Ceftazidime	100 (5/5)	-
Cephalothin/lexin	60 (12/20)	92 (11/12)
Combination		
Amoxicillin/clavulanic acid	45 (9/20)	75 (9/12)
Carbapenem		
Imipenem	25 (1/4)	-
Aminoglycosides		
Amikacin	30 (6/20)	50 (6/12)
Gentamicin	20 (4/20)	33 (4/12)
Kanamycin	47 (9/19)	75 (9/12)
Tobramycin	80 (4/5)	-
Lincosamides		
Lincomycin	95 (19/20)	-
Lincomycin-spectinomycin	60 (12/20)	-
Potentiated sulfas		
Trimethoprim-sulphamethoxazole	45 (9/20)	75 (9/12)
Fluoroquinolones		
Orbifloxacin	40 (8/20)	67 (8/12)
Enrofloxacin	45 (9/20)	75 (9/12)
Tetracycline		
Oxytetracycline	35 (7/20)	50 (6/12)
Amphenicols		
Chloramphenicol	60 (9/15)	75 (9/12)

MDR=Multidrug-resistant

Table-2: Antibiotics resistance patterns of *Acinetobacter baumannii* isolated from dog samples presented in a veterinary academic hospital in South Africa.

Patterns	Number
AMI_CEP_CHL_OXY_ENR_GEN_KAN_ORB_SUL_SYN	3
AMI_CEP_CHL_OXY_ENR_KAN_ORB_SUL_SYN	2
CEP_CHL_SYN	2
CEP_CHL_ENR_GEN_KAN_ORB_SUL_SYN	1
CEP_OXY_ENR_ORB_SUL_SYN	1
CEP_CHL_ENR_KAN_ORB_SUL	1
AMI_CEP_KAN	1
ENR_KAN_SUL	1
Total	12

AMI=Amikacin, CEP=Cephalothin/lexin, CHL=Chlorpenicol, OXY=Oxytetracycline, ENR=Enrofloxacin, GEN=Gentamicin, KAN=Kanamycin, ORB=Orbifloxacin, SUL=Trimethoprim-sulphamethoxazole SYN=Synulox

imipenem. *Klebsiella pneumoniae* exhibited a high prevalence of resistance to antibiotics belonging to aminoglycosides, tobramycin (88%), and kanamycin (63%). Ninety-four percentages (94%) of the isolates




Figure-2: Distribution of *Klebsiella pneumoniae* in the various canine clinical samples tested by the bacteriology laboratory at the faculty of veterinary science between 2007 and 2013.

were resistant to tylosin and 70% to oxytetracycline. One (n = 1) *K. pneumoniae* isolate tested showed resistance to both erythromycin and rifampin. Ninety-eight percentages (98%) of resistant *K. pneumoniae* isolates were MDR, with most being resistant to penicillin G (100%), lincomycin (98%), and tylosin tartrate (93%) (Table-3). The most common resistance pattern among the MDR *K. pneumoniae* isolates included the combination of lincomycin-penicillin G – tylosin (Table-4).

Discussion

This study investigated the AMR patterns of *A. baumannii* and *K. pneumoniae* isolated from dog cases presented at a veterinary hospital in South Africa. Similar to findings reported by other studies, *A. baumannii* and *K. pneumoniae* were isolated from various clinical samples. This confirms past research findings that reported these organisms as associated with various clinical infections in dogs [5, 7, 14–17]. Moreover, these organisms have been associated with nosocomial infections and can disseminate resistance genes to other bacteria [18, 19]. Cleaning and disinfection of the environment have proven effective in reducing the burden of these organisms in the environment [20]. However, these organisms can persist in a dry environment and continue to be a source of infection to susceptible patients [14, 20, 21]. Therefore, careful monitoring of dogs admitted to the veterinary hospital through routine surveillance is important to prevent the transmission of these pathogens between patients.

Antibiotic resistance patterns of *A. baumannii*

Antibiotic resistance among *A. baumannii* isolates is increasing and is associated with increased morbidity, mortality, and treatment costs in the intensive care unit [22]. In this study, a high prevalence

Table-3: Antimicrobial resistance and multidrug resistance profile of *Klebsiella pneumoniae* isolated from canine clinical samples tested at a veterinary academic hospital, in South Africa.

Antimicrobial category	Resistant	
	Isolates (n) %	MDR isolates (n) %
Macrolides		
Erythromycin	100 (1/1)	-
Tylosine	94 (51/54)	93 (51/55)
β -lactams		
Penicillins		
Ampicillin	100 (56/56)	-
Carbenicillin	100 (7/7)	-
Penicillin G	100 (56/56)	100 (55/55)
Piperacillin	100 (8/8)	-
Cephalosporins		
Ceftazidime	100 (8/8)	-
Cephalothin/lexin	64 (35/55)	64 (35/55)
Combination		
Amoxicillin/clavulanic acid	60 (33/55)	60 (33/55)
Carbapenem		
Imipenem	0 (0/8)	-
Aminoglycosides		
Amikacin	48 (27/56)	49 (27/55)
Gentamicin	41 (23/56)	42 (23/55)
Kanamycin	63 (33/52)	60 (33/55)
Tobramycin	88 (7/8)	-
Lincosamides		
Lincomycin	100 (54/54)	-
lincomycin-spectinomycin	72 (38/53)	-
Rifamycin		
Rifampin	100 (1/1)	-
Potentiated sulfas		
Trimethoprim-sulphamethoxazole	36 (20/56)	36 (20/55)
Fluoroquinolones		
Enrofloxacin	39 (22/56)	38 (21/55)
Orbifloxacin	49 (26/53)	47 (26/55)
Amphenicols		
Chloramphenicol	41 (19/46)	35 (19/55)
Tetracycline		
Oxytetracycline	70 (39/56)	71 (39/55)

MDR=Multidrug-resistant

of resistance among *A. baumannii* to β -lactam antimicrobials, including penicillin, cephalosporins, and amoxicillin/clavulanic acids, was observed. This is concerning as these antimicrobials are commonly used in small animal practices to treat uncomplicated infections [4]. The high prevalence of resistance observed in this study is consistent with that reported in veterinary studies conducted in the United States of America [23], Switzerland [24], and Malaysia [4]. This is attributed to the wide array of antimicrobial-inactivating enzymes, including β -lactamases, that confer resistance to the β -lactam groups of antimicrobials [18, 24, 25] and the overexpression of the chromosomally encoded AmpC cephalosporinases conferring resistance to broad-spectrum cephalosporins [25, 26].

A low prevalence of resistance to imipenem among *A. baumannii* has been reported in a study by Pailhoriès *et al.* [14]. In this study, only one (1/4) isolate was resistant to imipenem. However, a larger

Table-4: Antibiotics resistance patterns MDR-*Klebsiella pneumoniae* isolated from dog samples presented in a veterinary academic hospital in South Africa.

Pattern	Number
LIN_PNG_TYL	7
AMI_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SYN_TYL	3
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	2
AMI_CEF_CEP_CHL_OXY_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	2
AMI_CEF_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	2
AMI_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	2
AMI_CEP_OXY_GEN_KAN_LIN_LCS_PNG_SYN_TYL	2
CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
OXY_LIN_LCS_PNG_SUL_TYL	1
LIN_LCS_PNG_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
OXY_LIN_PNG_SYN_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_TYL	1
AMI_CEP_CHL_OXY_GEN_KAN_LIN_PNG_SYN_TYL	1
AMI_CEP_OXY_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
AMI_CEP_CHL_OXY_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
CEP_CHL_OXY_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
OXY_LIN_LCS_PNG_TYL	1
CEP_ENR_KAN_LIN_ORB_PNG_SYN_TYL	1
AMI_CEP_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_SUL_SYN_TOB_TYL	1
CEP_OXY_ENR_KAN_LIN_LCS_ORB_PNG_SYN_TYL	1
CEP_CHL_OXY_ENR_LIN_LCS_ORB_PNG_SUL_SYN_TYL	1
CEP_OXY_LIN_LCS_PNG_TYL	1
ENR_LIN_PNG_TYL	1
CEP_KAN_LIN_LCS_PNG_SUL_TYL	1
AMI_CEP_OXY_LIN_LCS_PNG_SUL_TYL	1
CEP_OXY_LIN_LCS_PNG_SUL_SYN_TYL	1
AMI_CEP_PNG_TYL	1
CEP_OXY_LIN_PNG_SYN_TYL	1
AMI_CHL_OXY_ENR_GEN_LIN_PNG_SUL_TYL	1
KAN_LIN_LCS_PNG_SYN_TYL	1
AMI_OXY_KAN_LIN_LCS_PNG_TYL	1
LIN_PNG_SYN	1
AMI_CEF_CEP_CHL_OXY_ENR_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	1
OXY_KAN_LIN_LCS_PNG_TYL	1
AMI_CEF_CEP_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TYL	1
OXY_LIN_LCS_PNG_SYN_TYL	1
AMI_CEP_CHL_OXY_KAN_LIN_ORB_PNG_SYN_TYL	1
OXY_LIN_PNG	1
AMK_GEN_KAN_LIN_LNC_PNG	1
CEF_CEP_CHL_OXY_ENR_ERT_GEN_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	1
CEF_CEP_CHL_OXY_ENR_KAN_LIN_LCS_ORB_PNG_PIP_SUL_SYN_TOB_TYL	1
PNG_PIP_SUL_SYN_TOB_TYL	1
Grand Total	55

AMI=Amikacin, CEF=Ceftazidime, CEP=Cephalothin/lexin, CHL=Chloramphenicol, OXY=Oxytetracycline, Enr=Enrofloxacin, ERT=Erythromycin, GEN=Gentamicin, KAN=Kanamycin, LIN=Lincomycin, LCS=Lincospectin, ORB=Orbifloxacin, PNG=Penicillin G, PIP=Piperacillin, RIF=Rifampin, SUL=Trimethoprim-sulphamethoxazole, SYN=Synulox, TOB=Tobramycin, TYL=Tylosine Tartrate, MDR=Multidrug-resistant

sample size is needed to determine the carbapenem susceptibility profile of *A. baumannii*, considering it

is the treatment of choice in humans [5].

Acinetobacter baumannii was resistant to trimethoprim-sulphamethoxazole, which is consistent with findings in other studies [27, 28]. This could be due to the overproduction or alteration in plasmid-mediated dihydrofolate reductase associated with trimethoprim resistance [29]. Although *A. baumannii* exhibited resistance to trimethoprim-sulphamethoxazole, evidence suggests that it should be considered for uncomplicated infections [28, 30, 31].

Resistance to aminoglycosides among *A. baumannii* was generally not common in this study, with the exception of tobramycin. This was expected given that resistance to tobramycin among *A. baumannii* increased [32, 33], mainly associated with the synthesis of aminoglycoside-modifying enzymes (AME) and efflux pump systems [32, 34]. This finding has significant public health implications, given that aminoglycosides are commonly used to treat *A. baumannii* infections. Therefore, trends in the susceptibility of these organisms should be monitored [25, 32].

Fluoroquinolones are generally used to treat *A. baumannii* infections in small animals [4]. In this study, a low prevalence of resistance to fluoroquinolones was observed. These organisms' resistance to fluoroquinolones could be due to the overuse of antibiotics and is mediated by efflux-mediated quinolones resistance [26, 35–37]. Therefore, care is needed to prevent misuse and overuse of fluoroquinolones to curb the development of resistance [38, 39]. A low prevalence of resistance to oxytetracycline was also observed in this study. This is encouraging due to the potential use of tetracyclines as monotherapy or in combination with other antimicrobials for the treatment of *A. baumannii* infections [27, 40, 41].

Forty-five percentages ($n = 5$; 45%) of *A. baumannii* isolates were MDR. However, a higher prevalence of *A. baumannii* (83.3%, 5/6) from environmental samples exhibiting MDR was reported by Ng *et al.* [4] in a study conducted in Malaysia. The high prevalence of MDR *A. baumannii* is not uncommon [42]. Given this, available evidence suggests that the choices for treatment of MDR *A. baumannii* infections may include carbapenems, colistin, and combination antimicrobials [4, 25, 32, 43].

Antibiotic resistance patterns of *K. pneumoniae*

Similar to the study conducted in South Korea [20] and France [44], most *K. pneumoniae* isolates in this study were resistant to β -lactam antimicrobials. The β -lactam resistance among *K. pneumoniae* isolates is attributed to the production of the plasmid-mediated sulphhydryl variable-1 a penicillinase [9, 17, 44–46]. However, none of the *K. pneumoniae* isolates in this study exhibited resistance to carbapenems. This is consistent with the findings of Haenni *et al.* [44] in a study conducted in France. These findings suggest that carbapenem could be considered as a treatment option for *K. pneumoniae* [46, 47].

The prevalence of resistance to aminoglycosides varied in this study. For example, low resistance was observed to amikacin and gentamycin [48, 49], while high resistance was observed to tobramycin and kanamycin. The varying prevalence of resistance among aminoglycosides could be attributed to the different resistance mechanisms. For example, resistance to amikacin and gentamicin is associated with the presence of enzymatic modification enzymes (AME) and/or 16S ribosomal RNA methyltransferase (16S-RMTases) [3, 48, 50], whereas tobramycin resistance is associated with the presence of the aminoglycoside N-acetyltransferases (6')-Ib(-like) protein and not AME or 16S-RMTase genes [51]. Despite the nephrotoxicity of aminoglycosides [52], this group of antimicrobials has been used effectively in the treatment of *K. pneumoniae* infections in both human and veterinary medicine [3].

Consistent with findings from both human and animal studies [16, 17, 46], resistance to enrofloxacin, and orbifloxacin among *K. pneumoniae* isolates was low in this study. Similar to other studies, resistance to trimethoprim-sulphamethoxazole was observed in this study [17, 36]. The low resistance in this study is encouraging, as trimethoprim-sulphamethoxazole is the drug of choice in the treatment of UTIs [17, 53]. In addition, trimethoprim-sulphamethoxazole is effective in the treatment of patients with carbapenemase-producing *K. pneumoniae* infections [54].

Almost all *K. pneumoniae* isolates in this study were MDR. This is not unusual, as AMR genes are frequently observed in this organism [17]. What is of concern is that the role of companion animals as reservoirs for human infections associated with resistant *K. pneumoniae* is not well described in the literature. Therefore, further studies are needed to investigate the transmission of resistant genes between humans and animals.

Limitation

The data used in this study were limited to one veterinary hospital and excluded other veterinary medical facilities. Since the hospital that provided the data is a referral hospital, it is possible that most isolates may have had previous exposure to antibiotics.

Conclusion

Acinetobacter baumannii and *K. pneumoniae* were identified from various clinical samples suggesting that they are important causes of infections in dogs and can infect various body systems. Both organisms exhibited a high prevalence of resistance to multiple antimicrobials. This has serious veterinary public health implications due to the negative impact on patient treatment and prognosis. Molecular studies are needed to identify genetic drivers of AMR among *A. baumannii* and *K. pneumoniae* organisms. In light of the high prevalence of AMR and MDR observed in this study, the need for strict infection prevention

and control measures to prevent the transmission of these organisms in hospital settings cannot be overemphasized.

Authors' Contributions

All authors were involved in the study design. DCS: Involved in the data collection and data management, performed all statistical analyses, interpreted the results, and prepared the draft manuscript. DNQ: Involved in data analysis and interpretation of the results, as well as extensive revision of the manuscript. JWO: Extensively reviewed and edited the manuscript. MMK: Involved in the editing of the manuscript. All authors have read, reviewed, and approved the final manuscript.

Acknowledgments

The authors thank the Academic Veterinary Teaching Hospital and Bacteriology Laboratory for providing the data. We also thank the Department of Language Services of the University of South Africa for their assistance with editing the manuscript. The authors did not receive any funds for this study.

Competing Interests

The authors declare that they have no competing interests.

Publisher's Note

Veterinary World remains neutral with regard to jurisdictional claims in published institutional affiliation.

References

- Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S. and Pardesi, K.R. (2019) Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Front. Microbiol.*, 10: 539.
- Ramsamy, Y., Essack, S.Y., Sartorius, B., Patel, M. and Mlisana, K.P. (2018) Antibiotic resistance trends of ESKAPE pathogens in Kwazulu-Natal, South Africa: A five-year retrospective analysis. *Afr. J. Lab. Med.*, 7(2): 887.
- Argudín, M.A., Deplano, A., Meghraoui, A., Dodémont, M., Heinrichs, A., Denis, O., Nonhoff, C. and Roisin, S. (2017) Bacteria from animals as a pool of antimicrobial resistance genes. *Antibiotics (Basel)*, 6(2): 12.
- Ng, S.Y., Saleha, A.A., Bejo, S.K. and Dhaliwal, G.K. (2016) Occurrence of multidrug-resistant *Acinetobacter baumannii* and *Escherichia coli* in veterinary healthcare facilities in Klang Valley, Malaysia. *J. Vet. Malaysia*, 28(2): 12–16.
- Francey, T., Gaschen, F., Nicolet, J. and Burnens, A.P. (2000) The role of *Acinetobacter baumannii* as a nosocomial pathogen for dogs and cats in an intensive care unit. *J. Vet. Intern. Med.*, 14(2): 177–183.
- Pendleton, J.N., Gorman, S.P. and Gilmore, B.F. (2013) Clinical relevance of the ESKAPE pathogens. *Expert Rev. Anti. Infect. Ther.*, 11(3): 297–308.
- Roberts, D.E., McClain, H.M., Hansen, D.S., Currin, P. and Howerth, E.W. (2000) An outbreak of *Klebsiella pneumoniae* infection in dogs with severe enteritis and septicemia. *J. Vet. Diagn. Invest.*, 12(2): 168–173.
- Marques, C., Belas, A., Aboim, C., Cavaco-Silva, P., Trigueiro, G., Gama, L.T. and Pomba, C. (2019) Evidence of sharing of *Klebsiella pneumoniae* strains between healthy companion animals and cohabiting humans. *J. Clin. Microbiol.*, 57(6):e01537–18.
- De Oliveira, D.M.P., Forde, B.M., Kidd, T.J., Harris, P.N.A., Schembri, M.A., Beatson, S.A., Beatson, S.A., Paterson, D.L. and Walker, M.J. (2020) Antimicrobial resistance in ESKAPE pathogens. *Clin. Microbiol. Rev.*, 33(3): e00181–19.
- Brink, A., Moolman, J., da Silva, M.C., Botha, M. and National Antibiotic Surveillance Forum. (2016) Antimicrobial susceptibility profile of selected bacteraemic pathogens from private institutions in South Africa. *S. Afr. Med. J.*, 97(4): 273–279.
- Crichton, H., O'Connell, N., Rabie, H., Whitelaw, A.C. and Dramowski, A. (2018) Neonatal and paediatric bloodstream infections: Pathogens, antimicrobial resistance patterns and prescribing practice at Khayelitsha district hospital, Cape Town, South Africa. *S. Afr. Med. J.*, 108(2): 99–104.
- Ricketts, S.W. (1995) Clinical veterinary microbiology P. J. Quinn, M. E. Carter and G. R. Carter Wolfe publishing. *Equine Vet. J.*, 27: 50.
- Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice, L.B., Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T. and Monnet, D.L. (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. *Clin. Microbiol. Infect.*, 18(3): 268–281.
- Pailhoriès, H., Belmonte, O., Kempf, M., Lemarié, C., Cuziat, J., Quinqueneau, C., Ramont, C., Joly-Guillou, M.L. and Eveillard, M. (2015) Diversity of *Acinetobacter baumannii* strains isolated in humans, companion animals, and the environment in Reunion Island: An exploratory study. *Int. J. Infect. Dis.*, 37: 64–69.
- Fournier, P.E. and Richet, H. (2006) The epidemiology and control of *Acinetobacter baumannii* in healthcare facilities. *Clin. Infect. Dis.*, 42(5): 692–699.
- Muggeo, A., Guillard, T., Klein, F., Reffuveille, F., François, C., Babosán, A., Bajole, O., Bertrand, X., De Champs, C. and CarbaFrEst Group. (2018) Spread of *Klebsiella pneumoniae* ST395 non-susceptible to carbapenems and resistant to fluoroquinolones in North-Eastern France. *J. Glob. Antimicrob. Resist.*, 13: 98–103.
- Marques, C., Menezes, J., Belas, A., Aboim, C., Cavaco-Silva, P., Trigueiro, G., Telo, Gama, L. and Pomba, C. (2019) *Klebsiella pneumoniae* causing urinary tract infections in companion animals and humans: Population structure, antimicrobial resistance and virulence genes. *J. Antimicrob. Chemother.*, 74(3): 594–602.
- Hung, K.H., Wang, M.C., Huang, A.H., Yan, J.J. and Wu, J.J. (2012) Heteroresistance to cephalosporins and penicillins in *Acinetobacter baumannii*. *J. Clin. Microbiol.*, 50(3): 721–726.
- Wyres, K.L. and Holt, K.E. (2018) *Klebsiella pneumoniae* as a key trafficker of drug resistance genes from environmental to clinically important bacteria. *Curr. Opin. Microbiol.*, 45: 131–139.
- Boerlin, P., Eugster, S., Gaschen, F., Straub, R. and Schawalder, P. (2001) Transmission of opportunistic pathogens in a veterinary teaching hospital. *Vet. Microbiol.*, 82(4): 347–359.
- Lee, D., Oh, J.Y., Sum, S. and Park, H.M. (2021) Prevalence and antimicrobial resistance of *Klebsiella* species isolated from clinically ill companion animals. *J. Vet. Sci.*, 22(2): e17.
- Jawad, A., Seifert, H., Snelling, A.M., Heritage, J. and Hawkey, P.M. (1998) Survival of *Acinetobacter baumannii* on dry surfaces: Comparison of outbreak and sporadic isolates. *J. Clin. Microbiol.*, 36(7): 1938–1941.
- Jaggi, N. (2012) *Acinetobacter baumannii* isolates in a tertiary care hospital: Antimicrobial resistance and clinical

- significance. *J. Microbiol. Infect. Dis.*, 2(7): 57–63.
24. Eveillard, M., Soltner, C., Kempf, M., Saint-André, J.P., Lemarié, C., Randrianarivelo, C., Seifert, H., Wolff, M. and Joly-Guillou, M.L. (2010) The virulence variability of different *Acinetobacter baumannii* strains in experimental pneumonia. *J. Infect.*, 60(2): 154–161.
 25. Maragakis, L.L. and Perl, T.M. (2008) *Acinetobacter baumannii*: Epidemiology, antimicrobial resistance, and treatment options. *Clin. Infect. Dis.*, 46(8): 1254–1263.
 26. Bonnin, R. and Nordmann, P. (2013) Screening and deciphering antibiotic resistance in *Acinetobacter baumannii*: A state of the art. *Expert Rev. Anti Infect. Ther.*, 11(6): 571–583.
 27. Kyriakidis, I., Vasileiou, E., Pana, Z.D. and Tragiannidis, A. (2021) *Acinetobacter baumannii* antibiotic resistance mechanisms. *Pathogens*, 10(3): 373.
 28. Nepka, M., Perivolioti, E., Kraniotaki, E., Politi, L., Tsakris, A. and Pournaras, S. (2016) *In vitro* bactericidal activity of trimethoprim-sulfamethoxazole alone and in combination with colistin against carbapenem-resistant *Acinetobacter baumannii* clinical isolates. *Antimicrob. Agents Chemother.*, 60(11): 6903–6906.
 29. Brolund, A., Sundqvist, M., Kahlmeter, G. and Grape, M. (2010). Molecular characterisation of trimethoprim resistance in *Escherichia coli* and *Klebsiella pneumoniae* during a two-year intervention on trimethoprim use. *PLoS One*, 5(2): e9233.
 30. Konca, C., Tekin, M. and Geyik, M. (2021) Susceptibility patterns of multidrug-resistant *Acinetobacter baumannii*. *Indian J. Pediatr.*, 88(2): 120–126.
 31. Raz-Pasteur, A., Liron, Y., Amir-Ronen, R., Abdelgani, S., Ohanyan, A., Geffen, Y. and Paul, M. (2019) Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant *Acinetobacter baumannii*: A retrospective matched cohort study. *J. Glob. Antimicrob. Resist.*, 17: 168–172.
 32. Tahbaz, S.V., Azimi, L. and Lari, A.R. (2019) Characterization of aminoglycoside resistance mechanisms in *Acinetobacter baumannii* isolates from burn wound colonization. *Ann. Burns Fire Disasters*, 32(2): 115–121.
 33. Upadhyay, S., Khyriem, A.B., Bhattacharya, P., Bhattacharjee, A. and Joshi, S.R. (2018) Undefined. High-level aminoglycoside resistance in *Acinetobacter baumannii* recovered from intensive care unit patients in Northeastern India. *Indian J. Med. Microbiol.*, 36(1): 43–48.
 34. Uwingabiye, J., Frikh, M., Lemnouer, A., Bssaibis, F., Belefquih, B., Maleb, A., Dahraoui, S., Belyamani, L., Bait, A., Haimeur, C., Louzi, L., Ibrahimi, A. and Elouennass, M. (2016) *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: Comparative study of intensive care units versus other hospital units. *Pan Afr. Med. J.*, 23: 191.
 35. Blondeau, J.M. (2004) Fluoroquinolones: Mechanism of action, classification, and development of resistance. *Surv. Ophthalmol.*, 49(Suppl 2): S73–S78.
 36. Lautenbach, E., Fishman, N.O., Bilker, W.B., Castiglioni, A., Metlay, J.P., Edelstein, P.H. and Strom, B.L. (2002) Risk factors for fluoroquinolone resistance in nosocomial *Escherichia coli* and *Klebsiella pneumoniae* infections. *Arch. Intern. Med.*, 162(21): 2469–2477.
 37. Schneiders, T., Amyes, S.G. and Levy, S.B. (2003) Role of AcrR and ramA in fluoroquinolone resistance in clinical *Klebsiella pneumoniae* isolates from Singapore. *Antimicrob. Agents Chemother.*, 47(9): 2831–2837.
 38. Piddock, L.J. (1998) Fluoroquinolone resistance: Overuse of fluoroquinolones in human and veterinary medicine can breed resistance. *BMJ*, 317(7165): 1020–1030.
 39. Cheng, V.C.C., Chen, J.H.K., So, S.Y.C., Wong, S.C.Y., Yan, M.K., Chau, P.H., Lee, W.M., To, K.K.W., Chan, J.F.W., Hung, I.F.N., Ho, P.L. and Yuen, K.Y. (2015) Use of fluoroquinolones is the single most important risk factor for the high bacterial load in patients with nasal and gastrointestinal colonization by multidrug-resistant *Acinetobacter baumannii*. *Eur. J. Clin. Microbiol. Infect. Dis.*, 34(12): 2359–2366.
 40. Rodríguez-Hernández, M., Pachón, J., Pichardo, C., Cuberos, L., Ibáñez-Martínez, J., García-curriel, A., Caballero, F.J., Moreno, I. and Jiménez-Mejías, M.E. (2000) Imipenem, doxycycline and amikacin in monotherapy and in combination in *Acinetobacter baumannii* experimental pneumonia. *J. Antimicrob. Chemother.*, 45(4): 493–501.
 41. Wood, G.C., Hanes, S.D., Boucher, B.A., Croce, M.A. and Fabian, T.C. (2003) Tetracyclines for treating multidrug-resistant *Acinetobacter baumannii* ventilator-associated pneumonia. *Intensive Care Med.*, 29(11): 2072–2076.
 42. Mishra, S.K., Rijal, B.P. and Pokhrel, B.M. (2013) Emerging threat of multidrug resistant bugs--*Acinetobacter calcoaceticus baumannii* complex and Methicillin resistant *Staphylococcus aureus*. *BMC Res. Notes*, 6(98): 1–6.
 43. Hetzler, L., Kollef, M.H., Yuenger, V., Micek, S.T. and Betthausen, K.D. (2022) New antimicrobial treatment options for severe Gram-negative infections. *Curr. Opin. Crit. Care*, 28(5): 522–533.
 44. Haenni, M., Ponsin, C., Métayer, V., Médaille, C. and Madec, J.Y. (2012) Veterinary hospital-acquired infections in pets with a ciprofloxacin-resistant CTX-M-15-producing *Klebsiella pneumoniae* ST15 clone. *J. Antimicrob. Chemother.*, 67(3): 770–771.
 45. Doorduyn, D.J., Rooijackers, S.H.M., Van Schaik, W. and Bardoel, B.W. (2016) Complement resistance mechanisms of *Klebsiella pneumoniae*. *Immunobiology*, 221(10): 1102–1109.
 46. Piperaki, E.T., Syrogiannopoulos, G.A., Tzouveleakis, L.S. and Daikos, G.L. (2017) *Klebsiella pneumoniae*: Virulence, biofilm and antimicrobial resistance. *J. Pediatr. Infect. Dis.*, 36(10): 1002–1005.
 47. Schmidt, J.S., Kuster, S.P., Nigg, A., Dazio, V., Brillhante, M., Rohrbach, H., Bernasconi, O.J., Büdel, T., Campos-Madueno, E.I., Brawand, S.G., Schuller, S., Endimiani, A., Perreten, V. and Willi, B. (2020) Poor infection prevention and control standards are associated with environmental contamination with carbapenemase-producing *Enterobacterales* and other multidrug-resistant bacteria in Swiss companion animal clinics. *Antimicrob. Resist. Infect. Control*, 9(1): 93.
 48. Shields, R.K., Clancy, C.J., Press, E.G. and Nguyen, M.H. (2016) Aminoglycosides for treatment of bacteremia due to carbapenem-resistant *Klebsiella pneumoniae*. *Antimicrob. Agents Chemother.*, 60(5): 3187–3192.
 49. Liang, C., Xing, B., Yang, X., Fu, Y., Feng, Y. and Zhang, Y. (2015) Molecular epidemiology of aminoglycosides resistance on *Klebsiella pneumoniae* in a hospital in China. *Int. J. Clin. Exp. Med.*, 8(1): 1381–1385.
 50. Landman, D., Bratu, S., Kochar, S., Panwar, M., Trehan, M., Doymaz, M. and Quale, J. (2007) Evolution of antimicrobial resistance among *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae* in Brooklyn, NY. *J. Antimicrob. Chemother.*, 60(1): 78–82.
 51. Yousfi, M., Touati, A., Muggeo, A., Mira, B., Asma, B., Brasme, L., Guillard, T. and de Champs, C. (2018) Clonal dissemination of OXA-48-producing *Enterobacter cloacae* isolates from companion animals in Algeria. *J. Glob. Antimicrob. Resist.*, 12: 187–191.
 52. Foudraïne, D.E., Strepis, N., Stingl, C., Ten Kate, M.T., Verbon, A., Klaassen, C.H.W., Klaassen, C.H.W., Goessens, W.H.F., Luider, T.M. and Dekker, L.J.M. (2021) Exploring antimicrobial resistance to beta-lactams, aminoglycosides and fluoroquinolones in *E. coli* and *K. pneumoniae* using proteogenomics. *Sci. Rep.*, 11(1): 12472.
 53. Li, Y., Fernández, R., Durán, I., Molina-López, R.A. and Darwich, L. (2021) Antimicrobial resistance in bacteria isolated from cats and dogs from the Iberian Peninsula. *Front. Microbiol.*, 11: 621597.
 54. Murri, R., Fiori, B., Spanu, T., Mastrorosa, I.,

Giovanneze, F., Taccari, F., Taccari, F., Palazzolo, C., Scoppetuolo, G., Ventura, G., Sanguinetti, M., Cauda, R. and Fantoni, M. (2017) Trimethoprim-sulfamethoxazole

therapy for patients with carbapenemase-producing *Klebsiella pneumoniae* infections: Retrospective single-center case series. *Infection*, 45(2): 209–213.
